Subscribe
shutterstock_1174421515_eyesonmilan
eyesonmilan / Shutterstock.com
9 May 2019Americas

Generic of Gilead’s HIV pre-exposure drug coming to market in 2020

A generic version of Gilead’s Truvada (emtricitabine/tenofovir disoproxil fumarate) will hit the market in 2020, a year earlier than expected.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Gilead accused of illegally paying to delay HIV drug competition
22 September 2020   Biopharmaceutical company Gilead is being sued for allegedly scheming to prevent a generic rival from releasing a competing version of its HIV drug Truvada, according to a class action lawsuit filed by investors in the drug manufacturer.
Americas
Gilead hit with antitrust suit over HIV drugs
16 January 2020   Gilead and its alleged co-conspirators Bristol-Myers Squibb, Japan Tobacco, and Johnson & Johnson have been accused of engaging in a long-running scheme to suppress competition in the market for HIV prevention therapies.
Americas
Gilead licenses HIV injections for $25m
24 July 2019   Gilead has obtained exclusive worldwide rights to market a long-acting injectable HIV product based on Durect Corporation’s Saber technology.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
Gilead accused of illegally paying to delay HIV drug competition
22 September 2020   Biopharmaceutical company Gilead is being sued for allegedly scheming to prevent a generic rival from releasing a competing version of its HIV drug Truvada, according to a class action lawsuit filed by investors in the drug manufacturer.
Americas
Gilead hit with antitrust suit over HIV drugs
16 January 2020   Gilead and its alleged co-conspirators Bristol-Myers Squibb, Japan Tobacco, and Johnson & Johnson have been accused of engaging in a long-running scheme to suppress competition in the market for HIV prevention therapies.
Americas
Gilead licenses HIV injections for $25m
24 July 2019   Gilead has obtained exclusive worldwide rights to market a long-acting injectable HIV product based on Durect Corporation’s Saber technology.

More on this story

Americas
Gilead accused of illegally paying to delay HIV drug competition
22 September 2020   Biopharmaceutical company Gilead is being sued for allegedly scheming to prevent a generic rival from releasing a competing version of its HIV drug Truvada, according to a class action lawsuit filed by investors in the drug manufacturer.
Americas
Gilead hit with antitrust suit over HIV drugs
16 January 2020   Gilead and its alleged co-conspirators Bristol-Myers Squibb, Japan Tobacco, and Johnson & Johnson have been accused of engaging in a long-running scheme to suppress competition in the market for HIV prevention therapies.
Americas
Gilead licenses HIV injections for $25m
24 July 2019   Gilead has obtained exclusive worldwide rights to market a long-acting injectable HIV product based on Durect Corporation’s Saber technology.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB